Fibroblast growth factor 21 as a biomarker for long‐term complications in organic acidemias. Issue 6 (29th August 2018)

• Record Type: Journal Article
• Authors: Molema, F.; Jacobs, E. H.; Onkenhout, W.; Schoonderwoerd, G. C.; Langendonk, J. G.; Williams, Monique
• Is Part Of: Journal of inherited metabolic disease. Volume 41:Issue 6(2018)
• Page Start: 1179
• Page End: 1187
• Publication Date: 2018-08-29
• Subjects: Metabolism, Inborn errors of -- Periodicals; Metabolism -- Disorders -- Periodicals; 616.39042
• DOI: 10.1007/s10545-018-0244-6
• Languages: English
• ISSNs: 0141-8955

Abstract

Abstract: Background: There is increasing evidence that long‐term complications in organic acidemias are caused by impaired mitochondrial metabolism. Currently, there is no specific biomarker to monitor mitochondrial dysfunction in organic acidemias. Serum fibroblast growth factor 21 (FGF‐21) is a biomarker for mitochondrial disease and could be a candidate to monitor mitochondrial function in the deleterious course of disease. Methods: Data of 17 patients with classical organic acidemias (11 propionic acidemia (PA), four methylmalonic acidemia (MMA) and two isovaleric acidemia (IVA) patients) were included. The clinical course was evaluated; metabolic decompensations and long‐term complications were correlated with plasma FGF‐21 levels. Cardiomyopathy, prolonged QT interval, renal failure, and optic neuropathy were defined as long‐term complications. Results: Patients ages ranged from 16 months up to 32 years. Serious long‐term complications occurred in eight patients (five PA and three MMA patients). In MMA and PA patients plasma FGF‐21 levels during stable metabolic periods were significantly higher in patients with long‐term complications ( Mdn = 2556.0 pg/ml) compared to patients without ( Mdn = 287.0 pg/ml). A median plasma FGF‐21 level above 1500 pg/ml during a stable metabolic period, measured before the occurrence of long‐term complications, had a positive predictive value of 0.83 and a negative predictive value of 1.00 on long‐term complications in MMA and PA patients. Conclusion: This study demonstrates the potential role of FGF‐21 as a biomarker for long‐term complications in classical organic acidemias, attributed to mitochondrial dysfunction.